TerminatedPhase 3NCT00322036

Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's

Studying Early-onset autosomal dominant Alzheimer disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Myrexis Inc.
Principal Investigator
Mark Laughlin, MD
Myrexis Inc.
Intervention
MPC-7869(drug)
Enrollment
800 target
Eligibility
55 years · All sexes
Timeline
20062008

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00322036 on ClinicalTrials.gov

Other trials for Early-onset autosomal dominant Alzheimer disease

Additional recruiting or active studies for the same condition.

See all trials for Early-onset autosomal dominant Alzheimer disease

← Back to all trials